2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Necchi A, Galsky M, Dizman N, Aggen D, Agarwal N, Al-Ahmadie H, Apolo A, Ballas L, Bangs R, Black P, Brausi M, Brembilla G, Cheng L, Chiti A, Cimadamore A, Colecchia M, Daneshmand S, Di Stasi S, Efstathiou J, Filicevas A, Geynisman D, Grivas P, Gupta S, Iasonos A, James N, Lerner S, Loriot Y, Makaroff L, Maluf F, Moschini M, Ostrovnaya I, Pal S, Plimack E, Prakash G, Psutka S, Rosenberg J, Sadeghi S, Schmidt B, Schwartz L, Sonpavde G, St Laurent M, Ye D, Spiess P, Kamat A. End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. Journal Of Clinical Oncology 2025, jco2501608. PMID: 40934451, PMCID: PMC12431632, DOI: 10.1200/jco-25-01608.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerInternational Bladder Cancer GroupClinical complete responseEvent-free survivalEvolving treatment landscapeBladder cancerDefinition of clinical complete responseConsensus definitionBladder-sparing treatmentCoprimary end pointsHigh-grade malignancyBladder cancer groupClinically meaningful benefitOrgan preservation strategiesEarly-phase studiesMultidisciplinary consensus panelIntention-to-treat approachBladder preservationSurgical consolidationComplete responseGenitourinary tumorsMetastatic diseaseUrine cytologyPerioperative strategiesPerioperative trialsPrediction of Oligometastatic Disease from Breast Cancer Using Next Generation Sequencing Genomics
Young P, Choi A, Hunting J, Ormond S, Wang Y, Douglas E, Ansley K, Cramer C, Li W, Whitlow C, Xing F, Soto-Pantoja D, Ruiz J, Chan M. Prediction of Oligometastatic Disease from Breast Cancer Using Next Generation Sequencing Genomics. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e233-e234. DOI: 10.1016/j.ijrobp.2025.06.3806.Peer-Reviewed Original ResearchOligometastatic diseaseOligometastatic progressionBreast cancerRisk scoreNext generation sequencingCumulative incidenceWidespread progressionWidespread diseaseMetastatic breast cancerFisher's exact testMetastatic diseaseChi-square testExtracranial diseaseDiffuse involvementWald chi-square testExact testCox regressionPatientsMedical recordsElectronic medical recordsStandard panelCancerPatients' scoresDiseaseSequenced genomesImpact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review
Myers S, Morton C, Bain P, Obeng-Gyasi S, Paskett E, McAlearney A, Greenup R, Minami C, Mittendorf E, King T. Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review. Journal Of Cancer Survivorship 2025, 1-8. PMID: 40884698, DOI: 10.1007/s11764-025-01881-7.Peer-Reviewed Original ResearchTreatment-related adverse eventsBreast cancerFinancial toxicityAdverse eventsNon-metastatic invasive breast cancerIncidence of breast cancerStage I-III breast cancerYoung breast cancer survivorsI-III breast cancerInvasive breast cancerYounger ageSystematic reviewPatient-reported outcome metricsBreast cancer survivorsYoung adultsTreatment-related symptomsMetastatic diseasePatient ageCancer histologyCancer survivorsEnglish-language publicationsImpact of agePrimary outcomePatientsCancerNeoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumabA randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
Zhang J, Cai J, Wang H, Yu Y, Bosch-Barrera J, Bernabé R, Andric Z, Badin F, Okuma Y, Paik P, Naidoo J, Kalofonos H, Wang B, Jotte R, Pennell N, Riess J, Doroshow D, Nishio M, Alatorre-Alexander J, Lu S. A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8664.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalFirst-line treatmentMetastatic non-small cell lung cancerCell lung cancerPD-1PD-L1Metastatic diseaseFirst-line treatment of metastatic non-small cell lung cancerLung cancerPD-L1 tumor proportion scoreTreatment of metastatic non-small cell lung cancerProgrammed cell death protein 1Cell death protein 1Programmed death-ligand 1Randomized phase 3 studyStandard first-line treatmentDevelopment of metastatic diseaseDisease control rateTumor proportion scoreDeath-ligand 1Platinum-doublet chemotherapyTargeting PD-1Duration of responseFirst-line therapyAdvance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review.
Xiang J, Wiese B, Patlovich K, Taylor J, Adelson K, Ratan R. Advance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24031.Peer-Reviewed Original ResearchSystemic anticancer therapyMonths of lifeTargeted therapyDose of treatmentAdvance care planning notesFinal treatmentAdvance care planningEnd-of-lifeHigher risk of mortalityDocumented discussionAssociated with decreased quality of lifeRisk of mortalityAssociated with decreased qualityMetastatic diseaseHigh healthcare useInpatient settingSolid tumorsRetrospective studyMD AndersonCellular therapyMedical oncologistsAnticancer therapyImmunotherapyTherapyPatientsImpact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B
Saperstein L, Rowe S, Gorin M, Pienta K, Siegel B, Morris M, Baskaran S, Stambler N, DiPippo V, Denes B. Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B. The Prostate 2025, 85: 1005-1015. PMID: 40320701, PMCID: PMC12211537, DOI: 10.1002/pros.24909.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive predictive valueMetastatic prostate cancerCohort B patientsConcomitant HTConcurrent HTHormone therapyDiagnostic performanceTestosterone levelsB patientsProstate cancerCohort BBaseline serum prostate-specific antigenMedian baseline prostate-specific antigenBaseline prostate-specific antigenMedian prostate-specific antigenElevated prostate-specific antigenSerum prostate-specific antigenImpact of hormone therapyConcomitant hormonal therapySuspected local recurrenceProstate cancer patientsSub-group analysisMedian exposure durationMetastatic diseaseAdvances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer
Smani S, DuBois J, Ajjawi I, Sohoni N, Choksi A, Lokeshwar S, Kim I, Renzulli J. Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer. Journal Of Clinical Medicine 2025, 14: 2565. PMID: 40283395, PMCID: PMC12028174, DOI: 10.3390/jcm14082565.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyAndrogen receptor signaling inhibitorsHormone-sensitive prostate cancerCombination therapyProstate cancerHigh-volume metastatic diseaseProgression to castration resistancePSMA PET-CTLow-volume diseaseOverall survival benefitCurrent treatment paradigmDetection of metastasesBalance treatment efficacyPersonalized treatment strategiesOptimal treatment selectionStandard of careCytoreductive prostatectomyDoublet therapyPrecision-based approachesTriplet therapyCastration resistanceDeprivation therapyMetastatic diseaseRadiation therapyCAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE
Meng X, Lotan Y, Kella N, Koch M, Pavlovich C, George A, Michel K, Sprenkle P, Sonn G, Mynderse L, Anttinen M, Chin J, Inman B, Mehan R, Banapour P, Sharif-Afshar A, Woodrum D, Ghanouni P, Arora S, Macura K, Princenthal R, Cohen M, Staruch R, Clarke G, Costa D, Klotz L. CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE. Urologic Oncology Seminars And Original Investigations 2025, 43: 79. DOI: 10.1016/j.urolonc.2024.12.200.Peer-Reviewed Original ResearchRadical prostatectomyRandomized Controlled TrialsProstate cancerAblation therapyAlternative to radiation therapyLocalized prostate cancerPCa-specific deathPad-free continencePrimary safety endpointPoor patient acceptanceStandard of careOrgan-confinedProstatectomy groupSignificant functional impairmentMetastatic diseaseRadiation therapyOpen-labelEfficacy endpointSecondary endpointsSafety endpointsSurgical approachPivotal studiesEfficacy dataNon-inferioritySub-sitesThe Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients
Antonios J, Adenu-Mensah N, Theriault B, Millares-Chavez M, Huttner A, Aboian M, Chiang V. The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients. Clinical And Translational Neuroscience 2025, 9: 10. DOI: 10.3390/ctn9010010.Peer-Reviewed Original ResearchCentral vein signRadiation necrosisTumor progressionDiagnosis of radiation necrosisDifferentiate RNCerebral radiation necrosisIntracranial metastatic diseaseCancer therapy responseMetastatic cancer patientsNon-invasive markerMetastatic diseaseSurgical biopsyTherapy responsePredictive markerPatient cohortPrimary treatmentRadiological toolsCancer patientsRadiological imagingTreatment decisionsPerivascular spacesPatientsTreatmentNecrosisMarkersComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, 66: 509-515. PMID: 39947910, PMCID: PMC11960611, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic targetFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabineSetdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma.
McGeary M, Damsky W, Daniels A, Lang S, Xu Q, Song E, Huet-Calderwood C, Lou H, Paradkar S, Micevic G, Kaech S, Calderwood D, Turk B, Yan Q, Iwasaki A, Bosenberg M. Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma. Cancer Immunology Research 2024, 13: 245-257. PMID: 39589394, DOI: 10.1158/2326-6066.cir-23-0514.Peer-Reviewed Original ResearchT cell infiltrationMHC-I expressionType I interferonImmune clearanceCD8+ T cell-dependent mannerIncreased CD8+ T cell infiltrationCD8+ T cell infiltrationDecreased MHC-I expressionAnti-cancer immune responseT cell-dependent mannerCD8+ T cellsDecreased T-cell infiltrationComplete tumor clearanceImmunity to melanomaIncreased melanoma growthInflamed tumor microenvironmentLoss of SETDB1Type I interferon receptorTreatment of melanomaType I Interferon SignalingWhole-genome CRISPR screenEndogenous retrovirusesType I interferon expressionMetastatic diseaseTumor clearanceGastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry
Yibrehu B, Mohammed T, Murthy S, Aderibigbe A, Daramola O, Arije O, Owoade I, Wuraola F, Olasehinde O, Betiku O, Folorunso S, Omoyiola O, Aderounmu A, Adisa A, Kingham P, Alatise O. Gastric Cancer at a Nigerian Tertiary Referral Center: Experiences With Establishing an Institutional Cancer Registry. Journal Of Surgical Oncology 2024, 131: 630-636. PMID: 39558548, DOI: 10.1002/jso.27993.Peer-Reviewed Original ResearchInstitutional cancer registryGastric cancerCancer RegistryTreatment modalitiesSuspected gastric cancerManagement of gastric cancerQuality of registry dataTertiary referral centerGastric cancer registryHigh-risk patientsDatabase of patientsGastric cancer databasePeriodic chart reviewMetastatic diseaseAdvanced diseaseReferral centerCancer DatabaseAvailability of robust dataMedian timeChart reviewFollow-upDeadly malignancyBlood workPatientsRegistry dataA multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Klughammer J, Abravanel D, Segerstolpe Å, Blosser T, Goltsev Y, Cui Y, Goodwin D, Sinha A, Ashenberg O, Slyper M, Vigneau S, Jané‐Valbuena J, Alon S, Caraccio C, Chen J, Cohen O, Cullen N, DelloStritto L, Dionne D, Files J, Frangieh A, Helvie K, Hughes M, Inga S, Kanodia A, Lako A, MacKichan C, Mages S, Moriel N, Murray E, Napolitano S, Nguyen K, Nitzan M, Ortiz R, Patel M, Pfaff K, Porter C, Rotem A, Strauss S, Strasser R, Thorner A, Turner M, Wakiro I, Waldman J, Wu J, Gómez Tejeda Zañudo J, Zhang D, Lin N, Tolaney S, Winer E, Boyden E, Chen F, Nolan G, Rodig S, Zhuang X, Rozenblatt-Rosen O, Johnson B, Regev A, Wagle N. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nature Medicine 2024, 30: 3236-3249. PMID: 39478111, PMCID: PMC11564109, DOI: 10.1038/s41591-024-03215-z.Peer-Reviewed Original ResearchClinicopathological featuresLocal T cell infiltrationT cell infiltrationMetastatic breast cancerBreast cancer biopsiesCancer-related deathsEpithelial-to-mesenchymal transitionMetastatic diseaseClinically relevant discoveriesTumor biopsiesTumor microenvironmentCancer biopsiesBreast cancerAnatomical sitesMacrophage populationsSingle-nucleus RNA sequencingBiopsyH&E stainingConsecutive serial sectionsClinical annotationTumorSingle-cellSpatial expression characteristicsSerial sectionsCell type compositionExamination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage
Moningi S, Ho J, Proudfoot J, Sutera P, Deek M, Phillips R, Rana Z, Molitoris J, Kwok Y, Mishra M, Spina C, Engelman A, Ross A, Liu Y, Davicioni E, Jia A, Spratt D, Leapman M, Tran P. Examination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s134-s135. DOI: 10.1016/j.ijrobp.2024.07.243.Peer-Reviewed Original ResearchDe novo metastasisDe novo metastatic diseaseGenomic classifierRadical prostatectomyMetastatic diseaseMetastatic patientsRetrospective analysisClinical data to dateMetastatic hormone-sensitive diseasePercentage of positive coresMedian percentagePelvic lymph node metastasisProstate cancer risk stratificationRetrospective analyses of clinical trialsLocal patient cohortNCCN risk groupHormone-sensitive diseaseLocalized prostate cancerGC scoresHigh-risk diseaseCohort of patientsLymph node metastasisCancer risk stratificationPrimary tumor tissuesProstate cancer diagnosisModern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-Escalation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply